Analysis of Potential Genotoxic Impurities in Active Pharmaceutical Ingredients (2)

Importance of the Topic

Monitoring potential genotoxic impurities (PGIs) in active pharmaceutical ingredients (APIs) is essential to ensure patient safety and meet stringent regulatory standards. Sulfonate esters, a class of PGIs, can induce DNA damage even at trace levels, making their accurate detection and quantification a critical aspect of pharmaceutical quality control.

Objectives and Study Overview

This study evaluated the performance of gas chromatography–mass spectrometry (GC-MS) for quantifying sulfonate ester PGIs in APIs. Two model compounds, gabexate mesylate and amlodipine besilate, were used to demonstrate the method’s sensitivity, linearity, and recovery. The work builds on previously established GC-MS conditions (Application Datasheet No. 18) and focuses on validation of quantitation and recovery in real API matrices.

Methodology and Instrumentation

Sample Preparation:

• Dissolve API in Milli-Q water at 10 mg/mL.
• Perform three successive solvent extractions with ethyl acetate (2 mL each), centrifuging at 2,000 rpm for 5 minutes to separate phases.
• Combine extracts and dehydrate with 1 g anhydrous sodium sulfate.
• Concentrate under nitrogen and reconstitute to 1 mL with acetic ether.

Instrumentation:

• Gas Chromatograph coupled to a Mass Spectrometer (GC-MS) following conditions from Datasheet No. 18.

Main Results and Discussion

Calibration and Linearity:

• Standard range: 0.01–10 µg/mL (equivalent to 1–1,000 ng/mg API).
• Correlation coefficients (R) ≥ 0.9996 across twelve sulfonate esters, confirming excellent linearity.

Spiked Recovery:

• Sulfonate esters spiked at 10 ng/mg in gabexate mesylate matrix.
• Average recoveries between 90.8% and 116.6%, with maximum RSD of 3.4% (n=5), demonstrating robust accuracy and precision.

API Analysis:

• Amlodipine besilate samples revealed four detectable sulfonate esters at concentrations ranging from 34.3 ng/mg to 5,122 ng/mg.

Benefits and Practical Applications

• High sensitivity and selectivity for trace-level PGIs.
• Straightforward sample preparation suitable for routine QC laboratories.
• Compliance with global regulatory guidelines on genotoxic impurities.

Future Trends and Possibilities

Advancements may include automated solid-phase extraction for improved throughput, integration of high-resolution mass spectrometry for enhanced selectivity, and expansion of the method to additional classes of genotoxic impurities. These developments will further streamline PGI monitoring in pharmaceutical workflows.

Conclusion

The GC-MS method presented offers a reliable, reproducible, and sensitive approach for quantification of sulfonate ester PGIs in APIs. Robust linearity, high recovery rates, and practical sample preparation position this protocol as a valuable tool for ensuring drug safety and regulatory compliance.

References

• Shimadzu GC-MS Application Datasheet No. 18: Analysis of Potential Genotoxic Impurities in Active Pharmaceutical Ingredients.
• Shimadzu LAAN-J-MS-E040: Application Datasheet for GCMS Analysis of PGIs.